Molecular structure of NF449, CAS Number: 627034-85-9
NF449 (CAS 627034-85-9)
See product citations (1)
Alternate Names:
4,4′,4′′,4′′′-[Carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid, octasodium salt
CAS Number:
627034-85-9
Molecular Weight:
1505.06
Molecular Formula:
C41H24N6Na8O29S8
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
NF449 is a potent and selective antagonist of the P2X1 receptor, a ligand-gated ion channel that is activated by extracellular ATP. When NF449 binds to the P2X1 receptor, it blocks the influx of cations such as calcium and sodium into the cell, thereby inhibiting the downstream signaling cascades that are normally initiated by P2X1 receptor activation. This interference with cellular signaling pathways can have a variety of effects, depending on the specific cell type and context. For example, in platelets, P2X1 receptor activation is involved in the aggregation response to vascular injury, so NF449 can inhibit this process. In smooth muscle cells, P2X1 receptor activation leads to vasoconstriction, so NF449 can relax blood vessels. In neurons, P2X1 receptor activation can lead to the release of neurotransmitters, so NF449 can modulate synaptic transmission. NF449′s ability to selectively block P2X1 receptor function makes it valuable for studying the physiological and pathophysiological roles of this receptor in various cellular processes.
NF449 (CAS 627034-85-9) References
- NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. | Braun, K., et al. 2001. Naunyn Schmiedebergs Arch Pharmacol. 364: 285-90. PMID: 11521173
- NF449, a novel picomolar potency antagonist at human P2X1 receptors. | Hülsmann, M., et al. 2003. Eur J Pharmacol. 470: 1-7. PMID: 12787824
- Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist. | Rettinger, J., et al. 2005. Neuropharmacology. 48: 461-8. PMID: 15721178
- Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]. | Hechler, B., et al. 2005. J Pharmacol Exp Ther. 314: 232-43. PMID: 15792995
- NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. | Krejci, P., et al. 2010. J Biol Chem. 285: 20644-53. PMID: 20439987
- Study of the reversal effect of NF449 on neuromuscular blockade induced by d-tubocurarine. | Su, TR., et al. 2011. Life Sci. 88: 1039-46. PMID: 21453711
- Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop. | El-Ajouz, S., et al. 2012. Br J Pharmacol. 165: 390-400. PMID: 21671897
- Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP. | Farmer, LK., et al. 2015. J Biol Chem. 290: 1559-69. PMID: 25425641
- The Suramin Derivative NF449 Interacts with the 5-fold Vertex of the Enterovirus A71 Capsid to Prevent Virus Attachment to PSGL-1 and Heparan Sulfate. | Nishimura, Y., et al. 2015. PLoS Pathog. 11: e1005184. PMID: 26430888
- A small-molecule screen identifies the antitrypanosomal agent suramin and analogues NF023 and NF449 as inhibitors of STAT5a/b. | Berg, A. and Berg, T. 2017. Bioorg Med Chem Lett. 27: 3349-3352. PMID: 28624143
- The ATP-gated P2X1 ion channel contributes to the severity of antibody-mediated Transfusion-Related Acute Lung Injury in mice. | El Mdawar, MB., et al. 2019. Sci Rep. 9: 5159. PMID: 30914724
- Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism. | Johansson, KE., et al. 2019. Sci Rep. 9: 14362. PMID: 31591425
- Suramin and NF449 are IP5K inhibitors that disrupt inositol hexakisphosphate-mediated regulation of cullin-RING ligase and sensitize cancer cells to MLN4924/pevonedistat. | Zhang, X., et al. 2020. J Biol Chem. 295: 10281-10292. PMID: 32493769
Inhibitor of:
0610012H03Rik, 0610037D15Rik, 0710008K08Rik, 1100001G20Rik, 1110002B05Rik, 1110059G10Rik, 4933402P03Rik, A1Up, A230065H16Rik, A26c2, A530099J19Rik, aC1, AMIGO1, ANKRD15, ANKRD33, ANKRD34A, ANKZF1, ANP32C, AP-2δ, APLNR, ARL10, AUTS2, BAHCC1, BC006662, BC011487, BC015286, BC016579, BC017647, BC018465, BPLP, BRINP2, BTBD19, BTNL8, C030046I01Rik, C11orf95, C12orf25, C14orf28, C16orf3, C16orf61, C17orf59, C17orf61, C19orf18, C1orf158_1700012P22Rik, C1orf174_A430005L14Rik, C1orf65, C1orf95, C330011K17Rik, C3orf33, C6orf203, C6orf211, C9orf47, C9orf78, C9orf85, CCDC105, CCDC12, CCDC23, CCDC49, CCDC73, CD39L4, CHL1, copine 7, CRISP-2, CXorf23, D55, DBNDD1, DCI, DUPD1, DYX2_D130043K22Rik, ERICH2, FAM188B2, FAM75A4, FAM75A7, FAM81B, FLJ22184, Gα 14, Gα i-3, Gα o, Gα s, Gβ 4, Gγ 11, Gγ 12, Gγ 9, Gγ4, G2A, GIPC3, Gm14496, GPA-16, Gpa2, GPR family (GPCR;G protein-coupled), GPR155, GPR179, GPR61, HECA, IGSF11, JAM4, JRKL, KIAA1618, LENG9, LEREPO4, LGICZ1, LOC100041249, LOC100041450, LOC643533, LOC643714, LOC645722, LOC646509, LOC647176, LOC727745, LOC728261, LOC728734, LOC728871, LOC729895, LOC729966, LOC730104, LOC730151, LOC730230, LRFN4, LRRC37A, LRRN1, MAGI-2, MORN5, MrgB5, MrgB8, Mrgprx3, NPR, NRN1L, NUDT8, OC-STAMP, Olah, Olfr1008, Olfr1014, Olfr1028, Olfr1029, Olfr1042, Olfr1043, Olfr1047, Olfr1048, Olfr1055, Olfr1061, Olfr1062, Olfr108, Olfr1086, Olfr1089, Olfr1097, Olfr1105, Olfr1274, Olfr747, Olfr847, Olfr849, Olfr871, Olfr872, Olfr873, Olr63, Olr831, OR10A4, OR1J2, OR1L1, OR3A4, OR4C16, OR6B2, Otospiralin, P2RY8, P2X3, P2X5, P2Y11, P2Y2, PAP21, PAWP, PDZD9, PHOSPHO2, PRAM-1, PRR7, PXK, Regulator of G protein signaling (RGS), RFPL4B, RGS16, RGS20, RIN1, RNFT1, SAPCD2, SMAP1L, SPEM1, SPNS3, SSB-3, STG, STON1-ALF, T2R04, T2R21, TARBP1, Tas2r103, TBC1D28, TBC1D3C, THA1P, TIGD7, TIPUH1, TM4-B, TMEM102, TMEM141, TMEM160, TMEM188, TTC39D, TTLL13, URE-B1, URO-9, USHBP1, UTP6, UXS1, V1RL1, VIPL, VMAC, Vmn1r119, Vmn1r125, Vmn1r126, Vmn1r142, Vmn1r149, Vmn1r160, Vmn1r90, Vmn1r91, Vmn2r17, Vmn2r43, Vmn2r57, Vmn2r7, Vmn2r71, Vmn2r72, ZSWIM6, and ZXDC.Activator of:
ARL7, BRAG2, C2CD3, C2orf53, C2orf68_0610030E20Rik, C9orf131, CD39L2, FAM70B, FCF1, granuphilin, ICE p20, LOC643278, LOC643933, LOC729181, Olfr544, OR1J2, OR2K2, ORNT1, ORNT2, P2X1, P2X4, Rab GDI α, RAIN, Ral A, RAMP3, TEX28, UNC93A, and WDR37.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NF449, 10 mg | sc-478179 | 10 mg | $203.00 | |||
NF449, 25 mg | sc-478179A | 25 mg | $469.00 | |||
NF449, 100 mg | sc-478179B | 100 mg | $1509.00 |